论文部分内容阅读
The title compound, (E)-4-(3-oxo-3-((4-(N-(pyrimidin-2-yl)sulfamoyl)-phenyl)ami- no)prop-1-en-1-yl)-1,2-phenylene diacetate dimethanol, was synthesized by the reaction of caffeic acid with sulfadiazine and characterized by FT-IR, 1 H-NMR spectroscopy, ESI-MS and X-ray single-crystal diffraction. It crystallizes in triclinic, space group P1 with a=10.302(7), b=11.621(8), c=12.107(8) , α=100.904(9), β=102.624(8), γ=95.501(9)o, V=1374.5(15) 3 , Z=2 , F(000)=588, Dc=1.354 Mg/m3 , Mr=560.57, μ=0.176 mm-1 , λ=0.71073 , the final R=0.0666 and wR=0.1950 for 4774 observed reflections with I > 2σ(I).
The title compound, (E) -4- (3-oxo-3- (4- (N- (pyrimidin-2- yl) sulfamoyl) -1,2-phenylene diacetate dimethanol, was synthesized by the reaction of caffeic acid with sulfadiazine and characterized by FT-IR, 1 H-NMR spectroscopy, ESI-MS and X-ray single-crystal diffraction. It crystallizes in triclinic, space group P1 with a = 10.302 (7), b = 11.621 (8), c = 12.107 (8) , α = 100.904 (9), β = 102.624 (8), γ = 95.501 (9) o, V = 1374.5 (15) 3, Z = 2, F (000) = 588, Dc = 1.354 Mg / m3, Mr = 560.57, μ = 0.176 mm-1, λ = 0.71073, the final R = 0.0666 and wR = 0.1950 for 4774 observed reflections with I> 2σ (I).